Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16466 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Ryan J Rakoczy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Miami University, Oxford, Ohio, USA. Hauptthemen laut MEDLINE: Psilocybin, Tryptamines, Agaricales, Hallucinogens. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PsyBio Therapeutics, Inc..
Abstract (Originalsprache)
Background and Purpose Demand for new antidepressants has resulted in a re‐evaluation of the therapeutic potential of psychedelic drugs. Several tryptamines found in psilocybin‐containing “magic” mushrooms share chemical similarities with psilocybin. Early work suggests they may share biological targets. However, few studies have explored their pharmacological and behavioural effects. Experimental Approach We compared baeocystin, norbaeocystin and aeruginascin with psilocybin to determine if they are metabolized by the same enzymes, similarly penetrate the blood–brain barrier, serve as ligands for similar receptors and modulate behaviour in rodents similarly. We also assessed the stability and optimal storage and handling conditions for each compound. Key Results In vitro enzyme kinetics assays found that all compounds had nearly identical rates of dephosphorylation via alkaline phosphatase and metabolism by monoamine oxidase. Further, we found that only the dephosphorylated products of baeocystin and norbaeocystin crossed a blood–brain barrier mimetic to a similar degree as the dephosphorylated form of psilocybin, psilocin. The dephosphorylated form of norbaeocystin was found to activate the 5‐HT 2A receptor with similar efficacy to psilocin and norpsilocin in in vitro cell imaging assays. Behaviourally, only psilocybin induced head twitch responses in rats, a marker of 5‐HT 2A ‐mediated psychedelic effects and hallucinogenic potential. However, like psilocybin, norbaeocystin improved outcomes in the forced swim test. All compounds caused minimal changes to metrics of renal and hepatic health, suggesting innocuous safety profiles. Conclusions and Implications Collectively, this work suggests that other naturally occurring tryptamines, especially norbaeocystin, may share overlapping therapeutic potential with psilocybin, but without causing hallucinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, Miami University, Oxford, Ohio, USA.
- Department of Chemical, Paper, and Biomedical Engineering, Miami University, Oxford, Ohio, USA.
ORCID-Profile: Matthew S McMurray
Förderung
- PsyBio Therapeutics, Inc.
Zitieren
APA
Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., Roberts, B. R., Sciortino, J. H., Gibbons, W. J., Friedberg, L. M., Jones, J. A., & McMurray, M. S. (2024). Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms. British Journal of Pharmacology. https://doi.org/10.1111/bph.16466
Vancouver
Rakoczy RJ, Runge GN, Sen AK, Sandoval O, Wells HG, Nguyen Q, et al. Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms. British Journal of Pharmacology. 2024. doi:10.1111/bph.16466
BibTeX
@article{Rakoczy2024,
author = {Rakoczy, Ryan J and Runge, Grace N and Sen, Abhishek K and Sandoval, Oscar and Wells, Hunter G and Nguyen, Quynh and Roberts, Brianna R and Sciortino, Jon H and Gibbons, William J and Friedberg, Lucas M and Jones, J Andrew and McMurray, Matthew S},
title = {Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16466}
}
EUVIMED